Fiche personne
Territoire
Alsace
Statut
Hospitalier
Affiliation
Recherche
Expertises :
- Recherche clinique
- Oncologie médicale
Publications
Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker.
Lindner ES, Admard J, Demidov G, Armeanu-Ebinger S, Sinnberg T, Niessner H, Amaral T, Garbe C, Forschner A, Kelemen O, Hilke FJ, Bonzheim I, Röcken M, Rieß O, Ossowski S, Schroeder C
Br J Cancer. 2026 04 9;:
Translating ctDNA into cutaneous melanoma care: An international expert survey.
Geidel G, Fekade N, Raabe K, Smit DJ, Adam L, Heidrich I, Rünger A, Kött J, Zell T, Amaral T, Ascierto PA, Corrie P, Dummer R, Eggermont A, Guo J, Hassel JC, Jalving M, Johnson DB, Kandolf L, Kirkwood JM, Lebbé C, Lee R, Long GV, Lorigan P, Malvehy J, Mangana J, Mohr P, Patel SP, Rizos H, Robert C, Schadendorf D, Sondak VK, Svane IM, Wainstein A, Zager JS, Pantel K, Hauschild A, Gebhardt C,
Eur J Cancer. 2026 03 19;239:116676
Insights into RAS-driven melanoma and its therapeutic implications.
Chatziioannou E, Lallas K, Sinnberg T, Niessner H, Stratigos AJ, Flatz L, Amaral T
Cancer Treat Rev. 2026 02;143:103090
Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.
Herold N, Bochem J, Leyens J, Wingerter S, Forchhammer S, Spreuer J, Deseke M, Yurttas C, Nocerino P, Antunes Dos Reis R, Amaral T, Wagner NB, Thiel K, Soffel D, Bieber K, Terheyden P, Wesch D, Oberg HH, Sebens S, Claassen M, Königsrainer A, Garbe C, Pawelec G, Meier F, Löffler MW, Weide B, Prinz I, Ravens S, Kordasti S, Eigentler T, Wistuba-Hamprecht K
J Immunother Cancer. 2026 01 20;14(1):
Predictive models of melanoma metastasis based on dermatoscopy in an international retrospective human reader study.
Lallas K, Kittler H, Tschandl P, Liopyris K, Amaral T, Argenziano G, Bakos RM, Braun R, Cabo H, Dika E, Malvehy J, Marghoob A, Puig S, Scope A, Stolz W, Minagawa A, Costa MM, Agozzino M, Shalmon D, Briatico G, Cohen Sabban EN, Mar V, Mahon C, Muller NM, Tanaka M, Liu T, Pham F, Alessandrini A, Chamberlain A, Vico-Alonso C, Thomas L, Soyer HP, Apalla Z, Vakirlis E, Zalaudek I, Lallas A
Nat Commun. 2025 12 8;16(1):10940
Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis.
Jimenez-Labaig P, Mirallas O, Martin-Quesada AI, Rullan A, Trapani D, Amaral T, Felip E, Tabernero J, Harrington KJ
J Immunother Cancer. 2025 11 28;13(11):
Genetic susceptibility in early-onset melanoma: An observational Greek cohort study.
Chatziioannou E, Kypreou K, Stefanaki I, Vatsellas G, Loupis T, Vrachnos DM, Plaka M, Champsas G, Sofopoulos M, Amaral T, Sinnberg T, Flatz L, Gogas H, Thanos D, Makrythanasis P, Stratigos AJ
J Eur Acad Dermatol Venereol. 2025 11 14;:
Characterization of long-term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021.
Laukhuf J, Wiens L, Grözinger G, Dittmann H, Thiel K, Leiter U, Amaral T, Nanz L, Flatz L, Reitmajer M, Forschner A
Int J Cancer. 2025 11 11;:
Messages for ultraviolet-radiation protection to fair-skinned populations.
Brochez L, Garbe C, Amaral T, Arenberger P, Astratinei V, Autier P, Berwick M, Bylaite M, Boonen B, Del Marmol V, Dreno B, Fargnoli MC, Green AC, Greinert R, Hauschild A, Harwood CA, Hoorens I, Kandolf L, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Leiter U, Lim HW, Longo C, Malvehy J, Moreno D, Östman F, Pellacani G, Peris K, Robert C, Ryll B, Saiag P, Schadendorf D, Soyer P, Spurrier-Bernard G, Stockfleth E, Stratigos A, Uhara H, Vieira R, Weinstock MA, Whitaker D, Whiteman DC, Zalaudek I, Forsea AM,
J Eur Acad Dermatol Venereol. 2025 11 6;:
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.
Kähler KC, Hassel JC, Ziemer M, Rutkowski P, Meier F, Flatz L, Gaudy-Marqueste C, Zimmer L, Santinami M, Russano F, von Wasielewski I, Eigentler TK, Maio M, Zalaudek I, Haferkamp S, Quaglino P, Welzel J, Röcken C, Enk A, Simon JC, Świtaj T, Garzarolli M, Amaral T, Malissen N, Livingstone E, Elia G, Covelli A, Lorizzo K, Neri D, Mulatto S, Parca A, Pizzichi B, Ascierto PA, Garbe C, Robert C, Schadendorf D, Hauschild A
Ann Oncol. 2025 10;36(10):1166-1177
Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients.
Ugurel S, Abu Rached N, Gambichler T, Mengoni M, Tüting T, Hassel JC, Reschke R, Lodde GC, Placke JM, Schadendorf D, Reinhardt L, Kreuter A, Gschnell M, Utikal J, Erdmann M, Dücker P, Helbig D, Franklin C, Gebhardt C, Poch G, Kähler KC, Weichenthal M, Gutzmer R, Heinzerling L, Weishaupt C, Mohr P, Thoms KM, Lang B, Schilling B, Haferkamp S, Sachse M, Welzel J, Jochims F, Raap U, Schley G, Terheyden P, Dippel E, Pöttgen C, Becker JC, Tasdogan A, Amaral T, Nanz L, Leiter U
Eur J Cancer. 2025 10 1;228:115750
Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and mutation.
Forschner J, Huynh J, Schroeder C, Armeanu-Ebinger S, Seibel-Kelemen O, Gschwind A, Bonzheim I, Eigentler TK, Amaral T, Ossowski S, Flatz L, Garbe C, Forschner A, Reitmajer M
Front Oncol. 2025 08 12;15:1618596
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).
Cherny NI, Oosting SF, Dafni U, Latino NJ, Galotti M, Zygoura P, Dimopoulou G, Amaral T, Barriuso J, Calles A, Kiesewetter B, Gomez-Roca C, Gyawali B, Piccart M, Passaro A, Roitberg F, Tarazona N, Trapani D, Curigliano G, Wester R, Zarkavelis G, Zielinski C, de Vries EGE
Ann Oncol. 2025 08;36(8):866-908
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study.
Mandalà M, Amaral T, Rutkowski P, Sergi MC, Rasch ML, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Dirven I, Tucci M, Guida M, Spagnolo F, Rossi E, Queirolo P, Quaglino P, Depenni R, Placzke J, Giacomo AMD, Del Vecchio M, Indini A, Silva IPD, Menzies AM, Hong A, Lorigan P, Long GV, Robert C, Ascierto PA
Eur J Cancer. 2025 07 25;225:115567
Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategies.
Jiménez-Labaig P, Mohamed F, Tan NJI, Sanna I, El Bairi K, Khan SZ, Akhade A, Amaral T, Trapani D, Patel A, Harrington KJ
Eur J Cancer. 2025 07 25;225:115564
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.
Grover P, Lo SN, Li I, Kuijpers AMJ, Kreidieh F, Williamson A, Amaral T, Dimitriou F, Placzke J, Olino K, Vitale MG, Saiag P, Gutzmer R, Allayous C, Olofsson Bagge R, Mattsson J, Asher N, Carter TJ, Meniawy TM, Lawless AR, Czapla JA, Warburton L, Gaudy-Marqueste C, Grob JJ, Collins RG, Zhang E, Kessels JI, Neyns B, Mehmi I, Hamid O, Julve M, Furness AJS, Margolin KA, Lev-Ari S, Ressler JM, Haque W, Khattak MA, Wicky A, Roberts-Thomson R, Arance A, Warrier G, Schollenberger MD, Parente P, Chatziioannou E, Lipson EJ, Michielin O, Weber JS, Hoeller C, Larkin J, Atkins MB, Essner R, Johnson DB, Sullivan RJ, Nathan P, Schachter J, Lebbe C, Ascierto PA, Kluger H, Rutkowski P, Dummer R, Garbe C, Lorigan PC, Burton E, Tawbi HA, Haanen J, Carlino MS, Menzies AM, Long GV
Ann Oncol. 2025 07;36(7):807-818
Psychosocial distress and persistent adverse events in long-term survivors of stage IV melanoma - a cross-sectional questionnaire study.
Reitmajer M, Schäffeler N, Bach A, Nanz L, Amaral T, Leiter U, Flatz L, Forschner A
J Dtsch Dermatol Ges. 2025 07;23(7):832-842
Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy.
Amaral T, Chatziioannou E, Nuebling A, Nanz L, Sinnberg T, Niessner H, Arentsen T, Ruiter R, Dwarkasing J, Eggermont AM, Leiter U, Flatz L, Forchhammer S
Eur J Cancer. 2025 05 2;220:115372
Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2.
Reitmajer M, Nanz L, Müller N, Leiter U, Amaral T, Aebischer V, Flatz L, Forschner A
Ther Adv Med Oncol. 2025 04 1;17:17588359251324035
Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028.
Donia M, Jespersen H, Jalving M, Lee R, Eriksson H, Hoeller C, Hernberg M, Gavrilova I, Kandolf L, Liszkay G, Helgadottir H, Zhukavets A, Pianova D, Marquez-Rodas I, Neyns B, Westgeest H, Pourmir I, Sobczuk P, Ellebaek E, Amaral T
ESMO Open. 2025 03;10(3):104295
Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis.
Lallas K, Chatziioannou E, Durak D, Frey G, Serna-Higuita LM, Rasch ML, Kyrgidis A, Timotheadou E, Apalla Z, Leiter U, Flatz L, Lallas A, Amaral T
Front Immunol. 2025 01 31;16:1524945
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.
McGillivray E, Ashouri K, Chatziioannou E, Gallegos JAO, Zarka J, Kechter J, Hwang AS, Zhang K, Barros M, Yeh J, Okazaki I, Crocker AB, Maeda T, Park SJ, Choi J, Andreoli M, Darwish T, Savage DJ, Kim KB, Gupta J, Shen J, Shirai K, Choi A, Pai L, Vazquez VL, Moser J, Amaral T, Hernandez Aya LF, Lutzky J, Najjar YG, Costello CM, Mangold AR, Bhatia S, Gibney GT, Farma JM, Daniels GA, Sosman J, Chandra S, Mangla A, Bollin K, Possik PA, Robles-Espinoza CD, Ito F, In GK
Br J Dermatol. 2025 01 24;192(2):316-326
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research.
Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, Donia M, Dummer R, Gutzmer R, Haushild A, Jalving M, Lee R, Lorigan P, Marquez-Rodas I, Michelin O, Nathan P, Robert C, Schadendorf D, Sobczuk P, Flatz L, Leiter U, Garbe C
Eur J Cancer. 2025 01 17;215:115160
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Brochez L, Del Marmol V, Dréno B, Eggermont AMM, Fargnoli MC, Forsea AM, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Leiter U, Longo C, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stockfleth E, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P, Mandala M,
Eur J Cancer. 2025 01 17;215:115152
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Brochez L, Del Marmol V, Dréno B, Eggermont AMM, Fargnoli MC, Forsea AM, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Leiter U, Longo C, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stockfleth E, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P, Mandala M,
Eur J Cancer. 2025 01 17;215:115153
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, Dummer R, Garbe C, Gershenwald JE, Gogas H, Guckenberger M, Haanen J, Hamid O, Hauschild A, Höller C, Lebbé C, Lee RJ, Long GV, Lorigan P, Muñoz Couselo E, Nathan P, Robert C, Romano E, Schadendorf D, Sondak V, Suijkerbuijk KPM, van Akkooi ACJ, Michielin O, Ascierto PA,
Ann Oncol. 2025 01;36(1):10-30
Exploring 'decision regret' in adjuvant-treated melanoma patients: Results from a cross-sectional survey on 200 participants.
Grünke T, Reiter S, Meyer S, Graf J, Schaeffeler N, Leiter U, Amaral T, Flatz L, Forschner A
J Eur Acad Dermatol Venereol. 2025 01;39(1):e63-e66
Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition.
Forschner A, Nanz L, Maczey-Leber Y, Amaral T, Flatz L, Leiter U
Int J Cancer. 2025 01 1;156(1):145-153
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Wyss N, Berner F, Walter V, Jochum AK, Purde MT, Abdou MT, Sinnberg T, Hofmeister K, Pop OT, Hasan Ali O, Bauer J, Cheng HW, Lütge M, Klümper N, Diem S, Kosaloglu-Yalcin Z, Zhang Y, Sellmer L, Macek B, Karbach J, König D, Läubli H, Zender L, Meyer BS, Driessen C, Schürch CM, Jochum W, Amaral T, Heinzerling L, Cozzio A, Hegazy AN, Schneider T, Brutsche MH, Sette A, Lenz TL, Walz J, Rammensee HG, Früh M, Jäger E, Becher B, Tufman A, Nuñez N, Joerger M, Flatz L
Am J Respir Crit Care Med. 2024 10 1;210(7):919-930
Improving assessment of lesions in longitudinal CT scans: a bi-institutional reader study on an AI-assisted registration and volumetric segmentation workflow.
Hering A, Westphal M, Gerken A, Almansour H, Maurer M, Geisler B, Kohlbrandt T, Eigentler T, Amaral T, Lessmann N, Gatidis S, Hahn H, Nikolaou K, Othman A, Moltz J, Peisen F
Int J Comput Assist Radiol Surg. 2024 09;19(9):1689-1697
Melanoma-specific survival of patients with uveal melanoma and liver metastases diagnosed between 2005 and 2021.
Wiens L, Grözinger G, Dittmann H, Thiel K, Leiter U, Amaral T, Nanz L, Flatz L, Forschner A
Ther Adv Med Oncol. 2024 08 23;16:17588359241273020
Adequate assessment yields appropriate care-the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO/SIOG Cancer in the Elderly Working Group.
Loh KP, Liposits G, Arora SP, Neuendorff NR, Gomes F, Krok-Schoen JL, Amaral T, Mariamidze E, Biganzoli L, Brain E, Baldini C, Battisti NML, Frélaut M, Kanesvaran R, Mislang ARA, Papamichael D, Steer C, Rostoft S
ESMO Open. 2024 08;9(8):103657
Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study.
Chatziioannou E, Higuita LMS, Kreft S, Kandolf L, Dujovic B, Reinhardt L, Tamara E, Marquez-Rodas I, Fortuna ARFP, Nübling A, Niessner H, Forschner A, Garbe C, Popovic A, Mirjana B, Meier F, Eigentler T, Leiter U, Flatz L, Sinnberg T, Amaral T
ESMO Open. 2024 08;9(8):103661
Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors?
Peisen F, Gerken A, Hering A, Dahm I, Nikolaou K, Gatidis S, Eigentler TK, Amaral T, Moltz JH, Othman AE
Cancers (Basel). 2024 07 26;16(15):
Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.
Garbe C, Forsea AM, Amaral T, Arenberger P, Autier P, Berwick M, Boonen B, Bylaite M, Del Marmol V, Dreno B, Fargnoli MC, Geller AC, Green AC, Greinert R, Hauschild A, Harwood CA, Hoorens I, Kandolf L, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Leiter U, Lim HW, Longo C, Malvehy J, Moreno D, Pellacani G, Peris K, Robert C, Saiag P, Schadendorf D, Peter Soyer H, Stockfleth E, Stratigos A, Uhara H, Vieira R, Volkmer B, Weinstock MA, Whitaker D, Zalaudek I, Whiteman DC, Brochez L
Eur J Cancer. 2024 06;204:114074
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, Dücker P, Ertl C, Tomsitz D, Tietze JK, Gutzmer R, Dabrowski E, Zimmer L, Gesierich A, Zierold S, French LE, Eigentler T, Amaral T, Heinzerling L
Eur J Cancer. 2024 05;203:114028
Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A sin
Wagner NB, Knierim SM, Luttermann F, Metzler G, Yazdi AS, Bauer J, Gassenmaier M, Forschner A, Leiter U, Amaral T, Garbe C, Eigentler TK, Forchhammer S, Flatz L
J Am Acad Dermatol. 2024 04;90(4):739-748
Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB.
Amaral T, Nanz L, Stadler R, Berking C, Ulmer A, Forschner A, Meiwes A, Wolfsperger F, Meraz-Torres F, Chatziioannou E, Martus P, Flatz L, Garbe C, Leiter U
Eur J Cancer. 2024 04;201:113912
Multidisciplinary approach and treatment of acral and mucosal melanoma.
Fortuna A, Amaral T
Front Oncol. 2024 02 26;14:1340408
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy.
Meraz-Torres F, Niessner H, Plöger S, Riel S, Schörg B, Casadei N, Kneilling M, Schaller M, Flatz L, Macek B, Eigentler T, Rieß O, Garbe C, Amaral T, Sinnberg T
J Exp Clin Cancer Res. 2024 01 23;43(1):30
Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017.
Reitmajer M, Leiter U, Nanz L, Amaral T, Flatz L, Garbe C, Forschner A
J Cancer Res Clin Oncol. 2024 01 18;150(1):15
Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy.
Peisen F, Gerken A, Dahm I, Nikolaou K, Eigentler T, Amaral T, Moltz JH, Othman AE, Gatidis S
PLoS One. 2024 01 5;19(1):e0296253
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner NB, Lenders MM, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler TK, Flatz L
Eur J Cancer. 2024 01;196:113425
Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma.
Nübel C, Amaral T, Leiter U, Flatz L, Forschner A
Front Oncol. 2023 11 30;13:1256800
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
Amaral T, Pop OT, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, Ring SS, Joerger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Hölzel M, Dummer R, Schürch CM, Forschner A, Flatz L
J Am Acad Dermatol. 2023 11;89(5):1072-1074
S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma" - update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention.
Leiter U, Heppt MV, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, ElGammal AKS, Felcht M, Flaig MJ, Follmann M, Fritz K, Grabbe S, Greinert R, Gutzmer R, Hauschild A, Hillen U, Ihrler S, John SM, Kofler L, Koelbl O, Krause-Bergmann A, Kraywinkel K, Krohn S, Langer T, Loquai C, Löser CR, Mohr P, Nashan D, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Voelter-Mahlknecht S, Vordermark D, Weichenthal M, Welzel J, Wermker K, Wiegand S, Garbe C, Berking C
J Dtsch Dermatol Ges. 2023 11;21(11):1422-1433
[S3-Leitlinie "Aktinische Keratose und Plattenepithelkarzinom der Haut" - Update 2023, Teil 2: Epidemiologie und Ätiologie, Diagnostik, Therapie des invasiven Plattenepithelkarzinoms der Haut, Nachsorge und Prävention: S3 guideline "actinic keratosis and
Leiter U, Heppt MV, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, El Gammal AKS, Felcht M, Flaig MJ, Follmann M, Fritz K, Grabbe S, Greinert R, Gutzmer R, Hauschild A, Hillen U, Ihrler S, John SM, Kofler L, Koelbl O, Krause-Bergmann A, Kraywinkel K, Krohn S, Langer T, Loquai C, Löser CR, Mohr P, Nashan D, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Voelter-Mahlknecht S, Vordermark D, Weichenthal M, Welzel J, Wermker K, Wiegand S, Garbe C, Berking C
J Dtsch Dermatol Ges. 2023 11;21(11):1422-1434
Can Whole-Body Baseline CT Radiomics Add Information to the Prediction of Best Response, Progression-Free Survival, and Overall Survival of Stage IV Melanoma Patients Receiving First-Line Targeted Therapy: A Retrospective Register Study.
Peisen F, Gerken A, Hering A, Dahm I, Nikolaou K, Gatidis S, Eigentler TK, Amaral T, Moltz JH, Othman AE
Diagnostics (Basel). 2023 10 14;13(20):
Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain.
Roitberg F, Amaral T, Cherny NI, Giuliani R, Latino NJ, Galotti M, Bricalli G, Curigliano G, Pentheroudakis G, Trapani D
ESMO Open. 2023 10;8(5):101617
Prognosis in stage II melanoma of the head and neck depends on the histological subtype.
Jasper S, Keim U, Leiter U, Amaral T, Flatz L, Forschner A
J Dtsch Dermatol Ges. 2023 10;21(10):1137-1146
S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma"- update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care.
Heppt MV, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, El Gammal AKS, Felcht M, Flaig MJ, Follmann M, Fritz K, Grabbe S, Greinert R, Gutzmer R, Hauschild A, Hillen U, Ihrler S, John SM, Kofler L, Koelbl O, Krause-Bergmann A, Kraywinkel K, Krohn S, Langer T, Loquai C, Löser CR, Mohr P, Nashan D, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Voelter-Mahlknecht S, Vordermark D, Weichenthal M, Welzel J, Wermker K, Wiegand S, Garbe C, Berking C
J Dtsch Dermatol Ges. 2023 10;21(10):1249-1262
Young oncologists' perspective on the role and future of the clinician-scientist in oncology.
Lim KHJ, Westphalen CB, Berghoff AS, Cardone C, Connolly EA, Güven DC, Kfoury M, Kocakavuk E, Mandó P, Mariamidze E, Matikas A, Moutafi M, Oing C, Pihlak R, Punie K, Sánchez-Bayona R, Sobczuk P, Starzer AM, Tečić Vuger A, Zhu H, Cruz-Ordinario MVB, Altuna SC, Canário R, Vuylsteke P, Banerjee S, de Azambuja E, Cervantes A, Lambertini M, Mateo J, Amaral T
ESMO Open. 2023 10;8(5):101625
[Die Prognose des Melanoms im Kopf-Hals-Bereich im Stadium II hängt vom histologischen Subtyp ab].
Jasper S, Keim U, Leiter U, Amaral T, Flatz L, Forschner A
J Dtsch Dermatol Ges. 2023 10;21(10):1137-1147
[S3-Leitlinie "Aktinische Keratose und Plattenepithelkarzinom der Haut" - Update 2023, Teil 1: Therapie der aktinischen Keratose, Morbus Bowen, Cheilitis actinica, berufsbedingte Erkrankung und Versorgungsstrukturen: S3 guideline "actinic keratosis and cu
Heppt MV, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, El Gammal AKS, Felcht M, Flaig MJ, Follmann M, Fritz K, Grabbe S, Greinert R, Gutzmer R, Hauschild A, Hillen U, Ihrler S, John SM, Kofler L, Koelbl O, Krause-Bergmann A, Kraywinkel K, Krohn S, Langer T, Loquai C, Löser CR, Mohr P, Nashan D, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Voelter-Mahlknecht S, Vordermark D, Weichenthal M, Welzel J, Wermker K, Wiegand S, Garbe C, Berking C
J Dtsch Dermatol Ges. 2023 10;21(10):1249-1262
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A
Nat Cancer. 2023 09;4(9):1292-1308
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.
Chatziioannou E, Roßner J, Aung TN, Rimm DL, Niessner H, Keim U, Serna-Higuita LM, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop OT, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T
EBioMedicine. 2023 07;93:104644
Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
Gaißler A, Bochem J, Spreuer J, Ottmann S, Martens A, Amaral T, Wagner NB, Claassen M, Meier F, Terheyden P, Garbe C, Eigentler T, Weide B, Pawelec G, Wistuba-Hamprecht K
J Immunother Cancer. 2023 06;11(6):
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GV
Nat Med. 2023 06;29(6):1310-1312
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.
Chatziioannou E, Leiter U, Thomas I, Keim U, Seeber O, Meiwes A, Boessenecker I, Gonzalez SS, Torres FM, Niessner H, Sinnberg T, Forschner A, Flatz L, Amaral T
Am J Clin Dermatol. 2023 05;24(3):453-467
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
Schumann K, Mauch C, Klespe KC, Loquai C, Nikfarjam U, Schlaak M, Akçetin L, Kölblinger P, Hoellwerth M, Meissner M, Mengi G, Braun AD, Mengoni M, Dummer R, Mangana J, Sindrilaru MA, Radmann D, Hafner C, Freund J, Rappersberger K, Weihsengruber F, Meiss F, Reinhardt L, Meier F, Rainer B, Richtig E, Ressler JM, Höller C, Eigentler T, Amaral T, Peitsch WK, Hillen U, Harth W, Ziller F, Schatton K, Gambichler T, Susok L, Maul LV, Läubli H, Debus D, Weishaupt C, Börger S, Sievers K, Haferkamp S, Zenderowski V, Nguyen VA, Wanner M, Gutzmer R, Terheyden P, Kähler K, Emmert S, Thiem A, Sachse M, Gercken-Riedel S, Kaune KM, Thoms KM, Heinzerling L, Heppt MV, Tratzmiller S, Hoetzenecker W, Öllinger A, Steiner A, Peinhaupt T, Podda M, Schmid S, Wollina U, Biedermann T, Posch C
J Eur Acad Dermatol Venereol. 2023 05;37(5):894-906
Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Amaral T, Sinnberg T, Chatziioannou E, Niessner H, Leiter U, Keim U, Forschner A, Dwarkasing J, Tjien-Fooh F, Wever R, Flatz L, Eggermont A, Forchhammer S
Eur J Cancer. 2023 03;182:155-162
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
Nuñez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L
Med. 2023 02 10;4(2):113-129.e7
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines.
Zarkavelis G, Amylidi AL, Verbaanderd C, Cherny NI, Metaxas Y, de Vries EGE, Zygoura P, Amaral T, Jordan K, Strijbos M, Dafni U, Latino N, Galotti M, Lordick F, Giuliani R, Pignatti F, Pentheroudakis G
ESMO Open. 2023 02;8(1):100604
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
Eckardt J, Schroeder C, Martus P, Armeanu-Ebinger S, Kelemen O, Gschwind A, Bonzheim I, Eigentler T, Amaral T, Ossowski S, Rieß O, Flatz L, Garbe C, Forschner A
J Cancer Res Clin Oncol. 2023 02;149(2):833-840
Medical Oncology Education in Europe: Equipping Medical Oncologists to Provide the Best Care for Patients with Cancer.
Jordan K, De Azambuja E, Amaral T, Strijbos M, Curigliano G, Lordick F
Oncol Res Treat. 2023 01 13;46(3):72-79
Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials.
Perez-Gracia JL, Penel N, Calvo E, Awada A, Arkenau HT, Amaral T, Grünwald V, Sanmamed MF, Castelo-Branco L, Bodoky G, Lolkema MP, Di Nicola M, Casali P, Giuliani R, Pentheroudakis G
Ann Oncol. 2023 01;34(1):70-77
Career and Professional Development for Young Oncologists.
Mair MJ, Cardone C, Connolly L, Kfoury M, Lambertini M, Lim J, Mariamidze E, Matikas A, Pihlak R, Punie K, Oing C, Sánchez-Bayona R, Sobczuk P, Zhu H, Berghoff AS, Amaral T
Oncol Res Treat. 2022 12 6;46(3):67-71
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis CC, Ascierto PA, Eggermont AMM, Grob JJ, Hauschild A, Sekulovic LK, Long GV, Luke JJ, Michielin O, Peris K, Schadendorf D, Kirkwood JM, Lorigan PC,
J Clin Oncol. 2022 11 10;40(32):3741-3749
Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms.
Aung TN, Shafi S, Wilmott JS, Nourmohammadi S, Vathiotis I, Gavrielatou N, Fernandez A, Yaghoobi V, Sinnberg T, Amaral T, Ikenberg K, Khosrotehrani K, Osman I, Acs B, Bai Y, Martinez-Morilla S, Moutafi M, Thompson JF, Scolyer RA, Rimm DL
EBioMedicine. 2022 08;82:104143
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
Gaißler A, Meldgaard TS, Heeke C, Babaei S, Tvingsholm SA, Bochem J, Spreuer J, Amaral T, Wagner NB, Klein R, Meier F, Garbe C, Eigentler TK, Pawelec G, Claassen M, Weide B, Hadrup SR, Wistuba-Hamprecht K
Front Immunol. 2022 07 7;13:906352
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Forsea AM, Grob JJ, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Lytvynenko B, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P,
Eur J Cancer. 2022 07;170:236-255
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Forsea AM, Grob JJ, Hoeller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Lytvynenko B, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P,
Eur J Cancer. 2022 07;170:256-284
Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing Immunotherapy.
Peisen F, Hänsch A, Hering A, Brendlin AS, Afat S, Nikolaou K, Gatidis S, Eigentler T, Amaral T, Moltz JH, Othman AE
Cancers (Basel). 2022 06 17;14(12):
Circulating tumor DNA (ctDNA) in the detection of relapse in melanoma patients with adjuvant anti-PD-1 therapy.
Forschner A, Niessner H, Sinnberg T, Eigentler T, Amaral T, Seith F, Garbe C, Biskup S, Battke F
J Dtsch Dermatol Ges. 2022 06;20(6):867-871
Zirkulierende Tumor-DNA (ctDNA) bei der Entdeckung von Rezidiven bei Melanompatienten mit adjuvanter Anti-PD-1-Therapie.
Forschner A, Niessner H, Sinnberg T, Eigentler T, Amaral T, Seith F, Garbe C, Biskup S, Battke F
J Dtsch Dermatol Ges. 2022 06;20(6):867-871
Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy.
Almansour H, Afat S, Serna-Higuita LM, Amaral T, Schraag A, Peisen F, Brendlin A, Seith F, Klumpp B, Eigentler TK, Othman AE
Acad Radiol. 2022 04;29(4):514-522
The impact of COVID-19 on oncology professionals-one year on: lessons learned from the ESMO Resilience Task Force survey series.
Lim KHJ, Murali K, Thorne E, Punie K, Kamposioras K, Oing C, O'Connor M, Élez E, Amaral T, Garrido P, Lambertini M, Devnani B, Westphalen CB, Morgan G, Haanen JBAG, Hardy C, Banerjee S
ESMO Open. 2022 02;7(1):100374
Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry.
Serna-Higuita LM, Amaral T, Forschner A, Leiter U, Flatz L, Seeber O, Thomas I, Garbe C, Eigentler TK, Martus P
Cancers (Basel). 2021 12 6;13(23):
Cutaneous melanoma attributable to UVR exposure in Denmark and Germany.
Keim U, Gandini S, Amaral T, Katalinic A, Holleczek B, Flatz L, Leiter U, Whiteman D, Garbe C
Eur J Cancer. 2021 12;159:98-104
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Bochem J, Zelba H, Spreuer J, Amaral T, Wagner NB, Gaissler A, Pop OT, Thiel K, Yurttas C, Soffel D, Forchhammer S, Sinnberg T, Niessner H, Meier F, Terheyden P, Königsrainer A, Garbe C, Flatz L, Pawelec G, Eigentler TK, Löffler MW, Weide B, Wistuba-Hamprecht K
J Immunother Cancer. 2021 12;9(12):
A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma.
Brendlin AS, Peisen F, Almansour H, Afat S, Eigentler T, Amaral T, Faby S, Calvarons AF, Nikolaou K, Othman AE
J Immunother Cancer. 2021 11;9(11):
The ESSO core curriculum committee update on surgical oncology.
van der Hage J, Sandrucci S, Audisio R, Wyld L, Søreide K, ,Amaral T, Audisio R, Bahadoer V, Beets G, Benstead K, Berge Nilsen E, Bol K, Brandl A, Braun J, Cufer T, Dopazo C, Edhemovic I, Eriksen JG, Fiore M, van Ginhoven T, Gonzalez-Moreno S, van der Hage J, Hutteman M, Masannat Y, Onesti EC, Rau B, De Reijke T, Rubio I, Ruurda J, Sandrucci S, Soreide K, Stattner S, Trapani D, D'Ugo D, Vriens M, Wyld L, Zahl Eriksson AG
Eur J Surg Oncol. 2021 11;47(11):e1-e30
The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II.
Lim KHJ, Murali K, Kamposioras K, Punie K, Oing C, O'Connor M, Thorne E, Amaral T, Garrido P, Lambertini M, Devnani B, Westphalen CB, Morgan G, Haanen JBAG, Hardy C, Banerjee S
ESMO Open. 2021 08;6(4):100199
Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036.
Garbe C, Keim U, Gandini S, Amaral T, Katalinic A, Hollezcek B, Martus P, Flatz L, Leiter U, Whiteman D
Eur J Cancer. 2021 07;152:18-25
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.
Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI
ESMO Open. 2021 06;6(3):100117
The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration.
Banerjee S, Lim KHJ, Murali K, Kamposioras K, Punie K, Oing C, O'Connor M, Thorne E, Devnani B, Lambertini M, Westphalen CB, Garrido P, Amaral T, Morgan G, Haanen JBAG, Hardy C
ESMO Open. 2021 04;6(2):100058
Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients.
Gambichler T, Tsagoudis K, Kiecker F, Reinhold U, Stockfleth E, Hamscho R, Egberts F, Hauschild A, Amaral T, Garbe C
Eur J Cancer. 2021 01;143:11-18
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.
Turiello R, Capone M, Giannarelli D, Morretta E, Monti MC, Madonna G, Mallardo D, Festino L, Azzaro R, Levesque MP, Imhof L, Weide B, Amaral T, Chevrier M, Sucker A, Rutkowski P, Schadendorf D, Lebbe C, Luke JJ, Wistuba-Hamprecht K, Dummer R, Pinto A, Morello S, Ascierto PA
J Immunother Cancer. 2020 12;8(2):
An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER study.
Amaral T, Niessner H, Sinnberg T, Thomas I, Meiwes A, Garbe C, Garzarolli M, Rauschenberg R, Eigentler T, Meier F
Neurooncol Adv. 2020 10 22;2(1):vdaa140
Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry.
Sarac E, Amaral T, Keim U, Leiter U, Forschner A, Eigentler TK, Garbe C
J Eur Acad Dermatol Venereol. 2020 09;34(9):2021-2025
Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients.
Hilke FJ, Sinnberg T, Gschwind A, Niessner H, Demidov G, Amaral T, Ossowski S, Bonzheim I, Röcken M, Riess O, Garbe C, Schroeder C, Forschner A
Cancers (Basel). 2020 08 20;12(9):
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.
Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, Hauschild A, Heinzerling L, Kiecker F, Schadendorf D, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zouboulis CC, Keilholz U, Testori A, Martus P, Leiter U, Eggermont AMM,
J Clin Oncol. 2020 08 1;38(22):2543-2551
Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase.
Glutsch V, Amaral T, Garbe C, Thoms KM, Mohr P, Hauschild A, Schilling B
Acta Derm Venereol. 2020 06 11;100(13):adv00174
ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy.
Perez-Gracia JL, Awada A, Calvo E, Amaral T, Arkenau HT, Gruenwald V, Bodoky G, Lolkema MP, Di Nicola M, Penel N, Vera R, Sanmamed MF, Douillard JY
ESMO Open. 2020 05;5(3):e000662
Late recurrence of melanoma after 10 years - Is the course of the disease different from early recurrences?
Sarac E, Wilhelmi J, Thomas I, Leiter U, Keim U, Eigentler TK, Garbe C, Amaral T
J Eur Acad Dermatol Venereol. 2020 05;34(5):977-983
Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?
Amaral T, Schulze M, Sinnberg T, Nieser M, Martus P, Battke F, Garbe C, Biskup S, Forschner A
Cancers (Basel). 2020 04 28;12(5):
Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma.
Amaral T, Seeber O, Mersi E, Sanchez S, Thomas I, Meiwes A, Forschner A, Leiter U, Eigentler T, Keim U, Garbe C
Cancers (Basel). 2020 04 22;12(4):
S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) - short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease.
Leiter U, Heppt MV, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kölbl O, Kraywinkel K, Löser C, Nashan D, Noor S, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Garbe C, Berking C
J Dtsch Dermatol Ges. 2020 04;18(4):400-413
[Not Available].
Leiter U, Heppt MV, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kölbl O, Kraywinkel K, Löser C, Nashan D, Noor S, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Garbe C, Berking C
J Dtsch Dermatol Ges. 2020 04;18(4):400-413
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T, Kiecker F, Schaefer S, Stege H, Kaehler K, Terheyden P, Gesierich A, Gutzmer R, Haferkamp S, Uttikal J, Berking C, Rafei-Shamsabadi D, Reinhardt L, Meier F, Karoglan A, Posch C, Gambichler T, Pfoehler C, Thoms K, Tietze J, Debus D, Herbst R, Emmert S, Loquai C, Hassel JC, Meiss F, Tueting T, Heinrich V, Eigentler T, Garbe C, Zimmer L,
J Immunother Cancer. 2020 03;8(1):
S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators.
Heppt MV, Leiter U, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kölbl O, Kraywinkel K, Löser C, Nashan D, Noor S, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Berking C, Garbe C
J Dtsch Dermatol Ges. 2020 03;18(3):275-294
[Not Available].
Heppt MV, Leiter U, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kölbl O, Kraywinkel K, Löser C, Nashan D, Noor S, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Berking C, Garbe C
J Dtsch Dermatol Ges. 2020 03;18(3):275-294
MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma.
Forschner A, Hilke FJ, Bonzheim I, Gschwind A, Demidov G, Amaral T, Ossowski S, Riess O, Schroeder C, Martus P, Klumpp B, Gonzalez-Menendez I, Garbe C, Niessner H, Sinnberg T
Cancers (Basel). 2020 02 26;12(3):
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Grob JJ, Höller C, Kaufmann R, Lallas A, Lebbé C, Malvehy J, Middleton M, Moreno-Ramirez D, Pellacani G, Saiag P, Stratigos AJ, Vieira R, Zalaudek I, Eggermont AMM,
Eur J Cancer. 2020 02;126:141-158
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Grob JJ, Höller C, Kaufmann R, Lallas A, Lebbé C, Malvehy J, Middleton M, Moreno-Ramirez D, Pellacani G, Saiag P, Stratigos AJ, Vieira R, Zalaudek I, Eggermont AMM,
Eur J Cancer. 2020 02;126:159-177
Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns.
Amaral T, Osewold M, Presser D, Meiwes A, Garbe C, Leiter U
J Eur Acad Dermatol Venereol. 2019 12;33 Suppl 8:44-51
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.
Heppt MV, Amaral T, Kähler KC, Heinzerling L, Hassel JC, Meissner M, Kreuzberg N, Loquai C, Reinhardt L, Utikal J, Dabrowski E, Gesierich A, Pföhler C, Terheyden P, Thoms KM, Zimmer L, Eigentler TK, Kirchberger MC, Stege HM, Meier F, Schlaak M, Berking C
J Immunother Cancer. 2019 11 13;7(1):299
Targeting tumor-resident mast cells for effective anti-melanoma immune responses.
Kaesler S, Wölbing F, Kempf WE, Skabytska Y, Köberle M, Volz T, Sinnberg T, Amaral T, Möckel S, Yazdi A, Metzler G, Schaller M, Hartmann K, Weide B, Garbe C, Rammensee HG, Röcken M, Biedermann T
JCI Insight. 2019 10 3;4(19):
Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.
Bochem J, Zelba H, Amaral T, Spreuer J, Soffel D, Eigentler T, Wagner NB, Uslu U, Terheyden P, Meier F, Garbe C, Pawelec G, Weide B, Wistuba-Hamprecht K
PLoS One. 2019 08 16;14(8):e0221301
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A, Battke F, Hadaschik D, Schulze M, Weißgraeber S, Han CT, Kopp M, Frick M, Klumpp B, Tietze N, Amaral T, Martus P, Sinnberg T, Eigentler T, Keim U, Garbe C, Döcker D, Biskup S
J Immunother Cancer. 2019 07 12;7(1):180
Time trends in incidence and mortality of cutaneous melanoma in Germany.
Garbe C, Keim U, Eigentler TK, Amaral T, Katalinic A, Holleczek B, Martus P, Leiter U
J Eur Acad Dermatol Venereol. 2019 07;33(7):1272-1280
Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis.
Amaral T, Tampouri I, Eigentler T, Keim U, Klumpp B, Heinrich V, Zips D, Paulsen F, Gepfner-Tuma I, Skardelly M, Tatagiba M, Tabatabai G, Garbe C, Forschner A
Immunotherapy. 2019 03;11(4):297-309
How to use neoadjuvant medical treatment to maximize surgery in melanoma.
Amaral T, Tampouri I, Garbe C
Expert Rev Anticancer Ther. 2018 02;18(2):121-130
Immunotherapy in managing metastatic melanoma: which treatment when?
Amaral T, Meraz-Torres F, Garbe C
Expert Opin Biol Ther. 2017 12;17(12):1523-1538
Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.
Amaral T, Leiter U, Garbe C
Rev Endocr Metab Disord. 2017 12;18(4):517-532
Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins.
Spänkuch I, Gassenmaier M, Tampouri I, Noor S, Forschner A, Garbe C, Amaral T
Eur J Cancer. 2017 08;81:203-205
Non-melanoma skin cancer: new and future synthetic drug treatments.
Amaral T, Garbe C
Expert Opin Pharmacother. 2017 05;18(7):689-699
Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).
Forschner A, Eichner F, Amaral T, Keim U, Garbe C, Eigentler TK
J Cancer Res Clin Oncol. 2017 03;143(3):533-540
MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.
Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C
Eur J Cancer. 2017 03;73:93-101
The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.
Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C
Eur J Cancer. 2017 03;73:85-92
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).
Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AMM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M
ESMO Open. 2016 12 7;1(6):e000107
Acquired resistance mechanisms to immunotherapy.
Amaral T, Garbe C
Ann Transl Med. 2016 12;4(24):547
The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
Amaral T, Nouri N, Garbe C
Expert Rev Anticancer Ther. 2016 07;16(7):705-15
